Collaborations & Alliances

Regeneron, Zai Lab Enter Strategic REGN1979 Alliance

Regeneron will receive $30 million upfront and is eligible to receive up to $160 million in additional regulatory and sales milestones.

By: Contract Pharma

Contract Pharma Staff

Regeneron Pharmaceuticals, Inc. and Zai Lab Ltd. entered a strategic collaboration for the development and commercialization of REGN1979 (CD20xCD3 bispecific antibody) in mainland China, Hong Kong, Taiwan and Macau. The collaboration will support global clinical development for REGN1979, starting with the ongoing Phase II program in B-cell non-Hodgkin lymphoma (B-NHL). If REGN1979 is approved, Zai Lab will leverage its capabilities to commercialize REGN1979 in this region. REGN1979 is the mos...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters